Literature DB >> 34551155

Type 2 diabetes mellitus promotes the proliferation, metastasis, and suppresses the apoptosis in oral squamous cell carcinoma.

Xin Hu1,2,3, Jin Wu1,2,3, Haofeng Xiong1,2,3,4, Liujun Zeng1,2,3, Zijia Wang1,2,3, Can Wang1,2,3, Danni Huang1,2,3, Tianyi Zhang1,2,3, Ying Peng1,2,3, Weijun Chen1,2,3, Kun Xia4, Tong Su1,2,3.   

Abstract

BACKGROUND: Our previous study revealed that patients with oral squamous cell carcinoma and concomitant type 2 diabetes mellitus presented a lower 5-year survival rate. Hyperglycemia has been increasingly recognized as a risk factor for more advanced disease and poorer prognosis in patients with oral squamous cell carcinoma. However, its role remains unclear.
METHODS: The expressions of BRIP1, Ki67, E-cadherin, and cleaved caspase-3 were detected by immunohistochemistry in oral squamous cell carcinoma tissues with or without type 2 diabetes mellitus. Cell counting kit-8 assay and wound healing assay were used to determine the proliferative and migratory ability of oral squamous cell carcinoma cells cultured with or without high glucose in vitro. Flow cytometry was applied to distinguish the role of high glucose on the cell cycle and apoptosis rates.
RESULTS: The expression level of Ki67 was elevated while BRIP1, E-cadherin, and cleaved caspase-3 were downregulated in patients with oral squamous cell carcinoma coexisting with diabetes. The cell proliferation and migration in oral squamous cell carcinoma cell lines were significantly enhanced by high glucose. Flow cytometric analysis suggested that high glucose predisposed cancer cells to stay at S/G2 phase and to exhibit lower apoptosis rates.
CONCLUSION: Our results implicated that type 2 diabetes mellitus may play a crucial role in the development and progression of oral squamous cell carcinoma through hyperglycemia, affecting cancer cell proliferation, migration, and apoptosis. This finding might provide a new direction for the prevention and treatment of oral squamous cell carcinoma.
© 2021 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.

Entities:  

Keywords:  biological behaviors; hyperglycemia; oral squamous cell carcinoma; type 2 diabetes mellitus

Mesh:

Substances:

Year:  2021        PMID: 34551155     DOI: 10.1111/jop.13244

Source DB:  PubMed          Journal:  J Oral Pathol Med        ISSN: 0904-2512            Impact factor:   4.253


  4 in total

1.  Point-of-care HbA1c Measurements in Oral Cancer and Control Patients in Hungary.

Authors:  Adam Vegh; Daniel Vegh; Dorottya Banyai; Gabor Kammerhofer; Zita Biczo; Balazs Voros; Marta Ujpal; Juan Francisco Peña-Cardelles; Zehra Yonel; Arpad Joob-Fancsaly; Peter Hermann; Zsolt Nemeth
Journal:  In Vivo       Date:  2022 Sep-Oct       Impact factor: 2.406

2.  Genetic Cross-Talk between Oral Squamous Cell Carcinoma and Type 2 Diabetes: The Potential Role of Immunity.

Authors:  Yunjian Fan; Jie Zhang; Jiayu Shi; Lin Chen; Jiazhen Long; Shuqi Zhang; Shuguang Liu
Journal:  Dis Markers       Date:  2022-05-19       Impact factor: 3.464

3.  Higher body mass index was associated with better prognosis in diabetic patients with stage II colorectal cancer.

Authors:  Xiao-Yu Liu; Bing Kang; Yu-Xi Cheng; Chao Yuan; Wei Tao; Bin Zhang; Zheng-Qiang Wei; Dong Peng
Journal:  BMC Cancer       Date:  2022-06-01       Impact factor: 4.638

4.  Metformin Downregulates the Expression of Epidermal Growth Factor Receptor Independent of Lowering Blood Glucose in Oral Squamous Cell Carcinoma.

Authors:  Wei-Ming Wang; Si-Si Yang; Shu-Hui Shao; Huan-Quan Nie; Jing Zhang; Tong Su
Journal:  Front Endocrinol (Lausanne)       Date:  2022-02-09       Impact factor: 5.555

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.